Citation

Mithoowani F. Drug. Ther. Persp. 2005; 21(5): 20-23.

Copyright

(Copyright © 2005)

DOI

10.2165/00042310-200521050-00007

PMID

unavailable

Abstract

Until recently, selective serotonin reuptake inhibitors (SSRIS) were widely prescribed off-label for the treatment of depression and other psychiatric conditions in children and adolescents. However, the UK Committee on Safety of Medicines and the US FDA have recommended caution in the use of SSRIs in this patient group because of an increased risk of suicidality. However, data supporting this warning appear to be equivocal.

Language: en

Keywords

United States; adult; human; United Kingdom; depression; drug use; suicide attempt; suicidal behavior; clinical trial; motivation; article; mental disease; behavior disorder; fluoxetine; fluvoxamine; paroxetine; serotonin uptake inhibitor; sertraline; venlafaxine; automutilation; anxiety disorder; sleep disorder; drug safety; food and drug administration; obsessive compulsive disorder